Results 81 to 90 of about 53,090 (292)

Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro

Blood, 2019
CD19 directed chimeric antigen receptor T cell (CART) therapy has shown remarkable activity in B cell lymphoma and acute lymphoblastic leukemia leading to the approval of two CART therapies. With the emergence of therapeutic anti-CD19 antibodies for the treatment of B cell malignancies, it remains to be elucidated whether such antibodies would ...
Paulina Horvei, Reona Sakemura, Michelle J. Cox, Claudia Manriquez Roman, Kendall J. Schick, Michael W. Ruff, Mehrdad Hefazi, Erin E. Tapper, Michael J. Hansen, Jürgen Schanzer, Jan Endell, Neil E. Kay, Grzegorz S. Nowakowski, Saad S. Kenderian   +13 more
openaire   +1 more source

Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone Marrow

, 2015
SummaryAntibody responses to viral infections are sustained for decades by long-lived plasma cells (LLPCs). However, LLPCs have yet to be characterized in humans.
Richard Burack, Iñaki Sanz, Slifka, Mark, Cheung, Wan Cheung, Jessica L. Halliley, Liping Zhao, Rosenberg, Alexander F., Lee, F. Eun-Hyung, Hao Wu, Igor Albizua, Denise Kaminiski, Ann R. Falsey, Ivan V. Gregoretti, Erika Hammarlund, Hammarlund, Erika, Falsey, Ann R., Walsh, Edward E., Darce, Jaime, Kaminiski, Denise, Sanz, Iñaki, Christopher F. Fucile, Kuang-Yueh Chiang, Fucile, Christopher F., Kyu, Shuya, Liesveld, Jane, Randall, Troy D., Wu, Hao, Edward E. Walsh, Wan Cheung Cheung, Albizua, Igor, Christopher M. Tipton, Burack, Richard, Shuya Kyu, Jane Liesveld, Halliley, Jessica L., Gregoretti, Ivan V., Alexander F. Rosenberg, Lana Popova, Tipton, Christopher M., Bradley, Kyle T., Troy D. Randall, F. Eun-Hyung Lee, Chiang, Kuang-Yueh, Popova, Lana, Zhao, Liping, Jaime Darce, Kyle T. Bradley, Mark Slifka   +47 more
core   +1 more source

SSR4 sustains Tertiary Lymphoid Structures by Regulation Quality Control of N‐linked Glycosylation During B‐cell Differentiation Into Plasmacyte in Colorectal Cancer

Advanced Science, EarlyView.
SSR4, a TRAP component induced in B cells, governs BAFFR N‐glycosylation via DDOST to sustain NF‐κB signaling, B‐cell differentiation, and TLS maturation. Its loss impairs anti‐tumor immunity, while overexpression improves antibody glycosylation and ADCC, revealing a critical regulator for cancer immunotherapy.
Wei Zhao, Youcai Zhao, Haiyang Li, Bowen Yang, Siyan Lu, Xueting Fu, Caixia Zhang, Yirong Chen, Xiaofeng Bian, Xinghua Ma, Xiaobing Yang, Bin Wang, Yuan Fang, Lulu Yang, Yelin Zhao, Shuli Zhao   +15 more
wiley   +1 more source

Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin’s lymphoma and characterization of the loss of the target antigen

Journal for ImmunoTherapy of Cancer
Background Infusion of T cells modified with a chimeric antigen receptor (CAR) targeting CD19 has achieved exceptional responses in patients with non-Hodgkin’s lymphoma (NHL), which led to the approval of CAR targeting CD19 (CART19) (Axi-cel and Liso-cel)
Manel Juan, Beatriz Martín-Antonio, Pablo Engel, Narcis Fernandez-Fuentes, Esperanza Esquinas, Alvaro Moreno-Sanz, Victor Sandá, Damian Stodulski-Ciesla, Jennifer Borregón, Virginia Peña-Blanque, Javier Fernández-Calles, Juana Serrano-Lopez, Pilar Llamas-Sillero, Laura Solán-Blanco   +13 more
doaj   +1 more source

Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain

Experimental Hematology & Oncology, 2023
Background Immunosuppression induced by programmed cell death protein 1 (PD1) presents a significant constraint on the effectiveness of chimeric antigen receptor (CAR)-T therapy. The potential of combining PD1/PDL1 (Programmed cell death 1 ligand 1) axis
Ang Zhang, Shenyu Wang, Yao Sun, Yikun Zhang, Long Zhao, Yang Yang, Yijian Zhang, Lei Xu, Yangyang Lei, Jie Du, Hu Chen, Lian Duan, Mingyi He, Lintao Shi, Lei Liu, Quanjun Wang, Liangding Hu, Bin Zhang   +17 more
doaj   +1 more source

Targeting of Antigens to B Lymphocytes via CD19 as a Means for Tumor Vaccine Development [PDF]

The Journal of Immunology, 2013
Abstract Ab therapy against surface Ags on tumor cells has demonstrated significant efficacy for some cancers. However, it is costly and patients frequently develop acquired resistance over time. In cases of Ab therapy resistance, T cell responses have been shown to be essential in controlling disease progression.
Yunfeng, Ma, Dong, Xiang, Jinwen, Sun, Chuanlin, Ding, Min, Liu, Xiaoling, Hu, Guoxin, Li, Goetz, Kloecker, Huang-Ge, Zhang, Jun, Yan   +9 more
openaire   +2 more sources

Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. [PDF]

, 2008
Contains fulltext : 70575.pdf (Publisher’s version ) (Open Access)Some minor histocompatibility antigens (mHags) are expressed exclusively on patient hematopoietic and malignant cells, and this unique set of antigens enables specific ...
Kelly van den Oudenalder, Mutis, T., Robbert M. Spaapen, Mark F. Leppert, Lokhorst, H.M., Leppert, M.F., Bloem, A.C., Otterud, Brith E., Spaapen, R.M., Minnema, M.C., Leppert, Mark F., Minnema, Monique C., Van Oudenalder, Kelly Den, Oudenalder, K. van den, Lokhorst, Henk M., Otterud, B.E., Monique C. Minnema, Tuna Mutis, Mutis, T, Henk M. Lokhorst, Bloem, Andries C., Dolstra, H., Dolstra, Harry, Andries C. Bloem, Brith E. Otterud, van den Oudenalder, K., Mutis, Tuna, Harry Dolstra, Spaapen, Robbert M.   +28 more
core   +1 more source

CCL3 and IL‐7 Synergistically Enhance CAR‐T Efficacy in Solid Tumors

Advanced Science, EarlyView.
Synergistic delivery of CCL3 and IL‐7 by CAR‐T cells overcomes the immunosuppressive tumor microenvironment by enhancing cell infiltration, survival, and local immune reprogramming. This also establishes positive feedback that amplifies anti‐tumor activity and memory responses in both CAR‐T and endogenous T cells, presenting a robust therapeutic ...
Huanpeng Chen, Xiaoyun Luo, Huixin Gao, Yujing Ke, Yu Zhan, Xiaoting Xu, Xiaoxiao Xiong, Fengjiao Wei, Si Yang, Zhonghua Liu, Bolan Yu, Zhaofeng Huang, Yingjie Bian   +12 more
wiley   +1 more source

Complement activation and protein adsorption by carbon nanotubes [PDF]

, 2006
As a first step to validate the use of carbon nanotubes as novel vaccine or drug delivery devices, their interaction with a part of the human immune system, complement, has been explored.
Flahaut, Emmanuel, Sim, Robert B., Sloan, Jeremy, Green, Malcolm L.H., Sim, Edith, Salvador-Morales, Carolina, Green, Malcolm L. H.   +6 more
core   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source